Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease

Abstract

These results provide insight into the efficacy and safety of batoclimab and support its further investigation as a potential therapy for TED.